It is probable that SARMs are less likely to result in the development of CVDs or other ailments, such as liver failure, when compared to other anabolic agents, such as T or AASs, because SARMs generally having lower potency and higher selectivity and specificity for the AR. This evidence concerns the gene AR and Hepatic failure.